Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML

Noah I. Hornick, Jianya Huan, Ben Doron, Natalya A. Goloviznina, Jodi Lapidus, Bill Chang, Peter Kurre

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.

Original languageEnglish (US)
Article number11295
JournalScientific Reports
Volume5
DOIs
StatePublished - Jun 12 2015

Fingerprint

Exosomes
MicroRNAs
Acute Myeloid Leukemia
Biomarkers
Serum
Recurrence
Residual Neoplasm
Bone Marrow
Tumor Burden
Heterografts
Mortality

ASJC Scopus subject areas

  • General

Cite this

Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML. / Hornick, Noah I.; Huan, Jianya; Doron, Ben; Goloviznina, Natalya A.; Lapidus, Jodi; Chang, Bill; Kurre, Peter.

In: Scientific Reports, Vol. 5, 11295, 12.06.2015.

Research output: Contribution to journalArticle

Hornick, Noah I. ; Huan, Jianya ; Doron, Ben ; Goloviznina, Natalya A. ; Lapidus, Jodi ; Chang, Bill ; Kurre, Peter. / Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML. In: Scientific Reports. 2015 ; Vol. 5.
@article{c314fa2da7f5407a9e7c6fe9ea54a933,
title = "Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML",
abstract = "Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.",
author = "Hornick, {Noah I.} and Jianya Huan and Ben Doron and Goloviznina, {Natalya A.} and Jodi Lapidus and Bill Chang and Peter Kurre",
year = "2015",
month = "6",
day = "12",
doi = "10.1038/srep11295",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Serum Exosome MicroRNA as a minimally-invasive early biomarker of AML

AU - Hornick, Noah I.

AU - Huan, Jianya

AU - Doron, Ben

AU - Goloviznina, Natalya A.

AU - Lapidus, Jodi

AU - Chang, Bill

AU - Kurre, Peter

PY - 2015/6/12

Y1 - 2015/6/12

N2 - Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.

AB - Relapse remains the major cause of mortality for patients with Acute Myeloid Leukemia (AML). Improved tracking of minimal residual disease (MRD) holds the promise of timely treatment adjustments to preempt relapse. Current surveillance techniques detect circulating blasts that coincide with advanced disease and poorly reflect MRD during early relapse. Here, we investigate exosomes as a minimally invasive platform for a microRNA (miRNA) biomarker. We identify a set of miRNA enriched in AML exosomes and track levels of circulating exosome miRNA that distinguish leukemic xenografts from both non-engrafted and human CD34+ controls. We develop biostatistical models that reveal circulating exosomal miRNA at low marrow tumor burden and before circulating blasts can be detected. Remarkably, both leukemic blasts and marrow stroma contribute to serum exosome miRNA. We propose development of serum exosome miRNA as a platform for a novel, sensitive compartment biomarker for prospective tracking and early detection of AML recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84931287779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931287779&partnerID=8YFLogxK

U2 - 10.1038/srep11295

DO - 10.1038/srep11295

M3 - Article

C2 - 26067326

AN - SCOPUS:84931287779

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 11295

ER -